Enzyme mutant, method for cascade catalytic synthesis of chiral S-4-phenyloxazolidinone and its application
Through the cascade catalysis of alcohol dehydrogenase and halohydrogenase mutants, the problems of low yield and poor selectivity of chiral S-4-phenyloxazolidinone synthesis in the prior art are solved, and high efficiency is achieved. Economical dual enzyme coupling catalytic synthesis, the yield and selectivity of the product are significantly improved, and are suitable for industrial applications.
Patent Information
- Application Number
- CN202410202142.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-23
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-02-23
AI Technical Summary
The prior art has low yield and poor stereoselectivity when synthesizing chiral S-4-phenyloxazolidinone, and the yield of single haloalcohol dehalogenase catalyzed synthesis is not more than 50%, and the atomic economy is not high.
Through the cascade catalysis of enzyme mutants, especially alcohol dehydrogenase mutants and halohydrogenase mutants, the amino acid sequence of the enzyme is adjusted to improve activity using 2-chloroacetophenone as the substrate, and the recombinant plasmid and The expression vector was expressed in E. coliBL21 (DE3) and was subjected to bienzyme coupling catalyzed.
The yield of S-4-phenyloxazolidinone is achieved above 90%, the ee value is greater than 99%, the regional selectivity is >99:1, it is easy to operate, has high atomic economy, and is suitable for industrial applications.
Smart Images

Figure CN118006574B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, in particular to an enzyme mutant, an alcohol dehydrogenase mutant and a method and application of cascade catalytic synthesis of chiral S-4-phenyloxazolidinone with halohydrin dehalogenase. Background Art
[0002] Oxazolidinone is a class of oxygen- and nitrogen-containing five-membered heterocyclic compounds, which are often used as bactericides and antimicrobial agents. It is also a class of highly valuable drug intermediates and can be used as precursors of β-amino acids. It has a wide range of applications in medicine. It was first reported in 1981. Since then, more and more chiral 4-substituted and 4,5-substituted-2-oxazolidinone compounds have been used as chiral auxiliary agents, and their clinical effectiveness has been verified in antibacterial, anti-asthmatic, and immunosuppressive agents. Linezolid is a drug with strong antibacterial effect. Among them, S-configured 4-aryl oxazolidinone can be used to synthesize the anti-hypercholesterol drug ezetimibe, and is also a key intermediate of the k-opioid receptor agonist CJ-15161, which has great utilization value. Oxazolidinone antibiotics are a class of novel fully synthetic antibiotics that mainly act on the initial stage of bacterial protein synthesis. Due to its unique mechanism of action, it has strong antibacterial activity against Gram-positive bacteria, and there is little cross-resistance problem, so it has always been widely concerned.
[0003] At present, the synthesis methods of chiral oxazolidinones and their derivatives mainly include chemical methods and biological methods. Chemical cyclization using chiral alcohols as raw materials has the disadvantages of high risk and high cost, and has strict restrictions on reaction temperature and requires a long reaction time. The use of biological methods to synthesize chiral oxazolidinone compounds mainly includes P450 monooxygenase and halohydrin dehalogenase catalyzing epoxide ring opening. The P450 monooxygenase method was reported by Rudi Fasan in 2015. Cytochrome P450 enzymes can effectively promote the activation and cyclization of carbonyl azido acid substrates to produce oxazolidinones through intramolecular nitre CH insertion reactions. However, the products obtained by this method are expensive and have many by-products. The use of halohydrin dehalogenase to generate 5-oxazolidinone was reported as early as 2008. Majerić Elenkov used cyanate as a nucleophile to test and found that under the action of halohydrin dehalogenase, the ring-opening product would quickly cyclize to 2-oxazolidinone. In this method, the ring is opened at the β site to generate 5-oxazolidinone. It was not until 2019 that Chen Yongzheng et al. first reported the synthesis of 4-aryl oxazolidinones using oxirane as a substrate and cyanate as a nucleophile using wild-type HheG. However, the stereoselectivity of the generated product was not high and the regioselectivity was poor. Ab HheG was modified to successfully obtain a highly regioselective product with an ee value of 99%. R-4-aryl oxazolidinones, and have been well applied in substrates with para- and meta-substituents ( E >200), but on the one hand, direct synthesis using halohydrin dehalogenase S -4-aryl oxazolidinones are rarely reported. On the other hand, the direct use of halohydrin dehalogenase to catalyze the synthesis of chiral oxazolidinones has a maximum yield of only 50%, and the atom economy is not high. Summary of the invention
[0004] The purpose of the present invention is to overcome the shortcomings of the prior art and provide an enzyme mutant, an alcohol dehydrogenase mutant and a cascade catalytic synthesis of chiral S -4-phenyloxazolidinone methods and uses.
[0005] The technical solution adopted by the present invention to solve its technical problem is:
[0006] An enzyme mutant with improved enzyme activity, the enzyme mutant is an alcohol dehydrogenase mutant and / or a halohydrin dehalogenase mutant, the alcohol dehydrogenase mutant is in the sequence of the original alcohol dehydrogenase shown in SEQ ID NO. 1 R The R position is a combination of R1, R2, R3 and R4, wherein R1 is phenylalanine at position 62, R2 is tryptophan at position 91, R3 is lysine at position 209, and R4 is alanine at position 249:
[0007] i: mutate the phenylalanine at position 62 to glutamic acid;
[0008] ii: mutate the tryptophan at position 91 to threonine;
[0009] iii: mutating the lysine at position 209 to arginine;
[0010] iv: mutate alanine at position 249 to serine;
[0011] Alternatively, the halohydrin dehalogenase mutant is a mutant in which the leucine at position 103 in the sequence of the original halohydrin dehalogenase shown in SEQ ID NO. 5 is mutated to glycine.
[0012] Further, the original alcohol dehydrogenase is derived from Pyrococcus furiosus ,name Pf ADH, the original nucleotide sequence is shown in SEQ ID NO.2;
[0013] Alternatively, the alcohol dehydrogenase mutant has the amino acid sequence shown in SEQ ID NO.3;
[0014] The halohydrin dehalogenase is derived from Ilumatobacter coccineusA halohydrin dehalogenase mutant HheG (L103G), wherein the nucleotide sequence of the original halohydrin dehalogenase is shown in SEQ ID NO.6;
[0015] The amino acid sequence of the halohydrin dehalogenase mutant is shown in SEQ ID NO.7, and the nucleotide sequence of the halohydrin dehalogenase mutant is shown in SEQ ID NO.8.
[0016] The encoding gene of the enzyme mutant as described above is shown in SEQ ID NO.4.
[0017] A recombinant plasmid carrying the gene as described above.
[0018] Preferably, the expression vector of the recombinant plasmid is pET28a(+), and the expression host is E.coli BL21(DE3).
[0019] A genetically engineered bacterium expressing the gene as described above.
[0020] The application of the enzyme mutant as described above in the synthesis of chiral S-4-phenyloxazolidinone.
[0021] An alcohol dehydrogenase mutant and a method for cascade catalytic synthesis of chiral S-4-phenyloxazolidinone with a halohydrin dehalogenase, comprising the following steps:
[0022] The alcohol dehydrogenase and halohydrin dehalogenase are present in the form of recombinant cells or crude enzyme solutions for catalysis;
[0023] Wherein, when the alcohol dehydrogenase and halohydrin dehalogenase are present in the form of recombinant cells for catalysis, the amount of alcohol dehydrogenase and halohydrin dehalogenase is 10-100 mg wet cells / ml;
[0024] When the alcohol dehydrogenase and the halohydrin dehalogenase are present in the form of crude enzyme solution for catalysis, the final concentration of the alcohol dehydrogenase and the halohydrin dehalogenase in the reaction system is 10-30 g / L;
[0025] The temperature of the catalytic reaction is 25-35°C, and the time of the catalytic reaction is 2-48 h.
[0026] Furthermore, the preparation method of alcohol dehydrogenase and halohydrin dehalogenase in the form of recombinant cells and crude enzyme solution is as follows:
[0027] Expressing alcohol dehydrogenase or halohydrin dehalogenase in a host cell to obtain a recombinant cell; or introducing a nucleic acid molecule capable of expressing alcohol dehydrogenase or halohydrin dehalogenase into the host cell, and inducing expression to obtain a recombinant cell;
[0028] Lysing the recombinant cells to obtain a crude enzyme solution;
[0029] Alternatively, 2-chloroacetophenone is added to the reaction system, and the final concentration of 2-chloroacetophenone in the reaction system is 20-200 mM;
[0030] Alternatively, the catalytic reaction is carried out in a buffer, wherein the buffer is a Tris-HCl buffer with a concentration of 50-100 mM and a pH of 7.0-9.0, and / or a phosphate buffer with a concentration of 50-100 mM and a pH of 6.0-8.0.
[0031] Furthermore, the induced expression is to add IPTG to the culture system to a final concentration of 0.1-0.6 mM, and induce the culture at 16-28° C. for 10-18 h;
[0032] The nucleic acid molecule capable of expressing alcohol dehydrogenase or halohydrin dehalogenase is introduced into the host cell in the form of a recombinant vector; the recombinant vector is a bacterial plasmid or yeast plasmid carrying a gene encoding the alcohol dehydrogenase or halohydrin dehalogenase;
[0033] The recombinant plasmid specifically replaces the alcohol dehydrogenase or halohydrin dehalogenase coding gene with the restriction site of the pET28a vector. Nde I and Xho I after the small fragment obtained recombinant plasmid.
[0034] The host cell is a prokaryotic cell or a eukaryotic cell; the prokaryotic cell is a bacterium, and the eukaryotic cell is a yeast cell;
[0035] Alternatively, in the alcohol dehydrogenase catalyzed reaction, the coenzyme is specifically reduced coenzyme I, namely NADH or reduced coenzyme II, namely NADPH;
[0036] Wherein, the final concentration of NADH in the reaction system is 50-200 mM;
[0037] The reaction concentration of NaOCN in the reaction system is 1.0-1.5 times the substrate concentration.
[0038] Furthermore, the bacteria may be Escherichia coli, preferably E.coli BL21(DE3).
[0039] The advantages and positive effects achieved by the present invention are:
[0040] 1. The present invention provides a new green biosynthetic route, using 2-chloroacetophenone as a substrate and synthesizing it through a double enzyme cascade catalysis S -4-phenyloxazolidinone, the product yield is more than 90%, the ee value is greater than 99%, and the regioselectivity is>99:1. The present invention is easy to operate, has high atom economy, and high yield. S-4-phenyloxazolidinone has good industrial application prospects.
[0041] 2. The present invention provides an alcohol dehydrogenase mutant and a halohydrin dehalogenase mutant, and their encoding genes, a recombinant plasmid containing the encoding genes, a genetically engineered bacterium containing the recombinant plasmid, and a double enzyme coupling method for preparing chiral S The application of -4-phenyloxazolidinone is aimed at solving the problems of low activity of original alcohol dehydrogenase and low regioselectivity of halohydrin dehalogenase, and the existing single halohydrin dehalogenase catalyzed synthesis of chiral S -The yield of 4-phenyloxazolidinone is less than 50%. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 In Example 3 of the present invention, the wild-type alcohol dehydrogenase and the wild-type halohydrin dehalogenase catalyze the synthesis of 2-chloroacetophenone ( S )-4-phenyloxazolidinone liquid chromatogram;
[0043] Figure 2 This is a liquid chromatogram of the synthesis of (S)-4-phenyloxazolidinone from 2-chloroacetophenone catalyzed by the alcohol dehydrogenase mutant and the halohydrin dehalogenase mutant in Example 3 of the present invention. DETAILED DESCRIPTION
[0044] The present invention will be further described below in conjunction with the embodiments. The following embodiments are descriptive rather than restrictive, and the protection scope of the present invention cannot be limited by the following embodiments.
[0045] The various experimental operations involved in the specific embodiments are all routine techniques in the art. For parts not specially annotated in this document, ordinary technicians in the art can implement them by referring to various commonly used reference books, scientific and technological literature or related instructions, manuals, etc. before the filing date of this invention.
[0046] An enzyme mutant with improved enzyme activity, the enzyme mutant is an alcohol dehydrogenase mutant and / or a halohydrin dehalogenase mutant, the alcohol dehydrogenase mutant is in the sequence of the original alcohol dehydrogenase shown in SEQ ID NO. 1 R The R position is a combination of R1, R2, R3 and R4, wherein R1 is phenylalanine at position 62, R2 is tryptophan at position 91, R3 is lysine at position 209, and R4 is alanine at position 249:
[0047] i: mutate the phenylalanine at position 62 to glutamic acid;
[0048] ii: mutate the tryptophan at position 91 to threonine;
[0049] iii: mutating the lysine at position 209 to arginine;
[0050] iv: mutate alanine at position 249 to serine;
[0051] Alternatively, the halohydrin dehalogenase mutant is a mutant in which the leucine at position 103 in the sequence of the original halohydrin dehalogenase shown in SEQ ID NO. 5 is mutated to glycine.
[0052] Preferably, the original alcohol dehydrogenase is derived from Pyrococcus furiosus ,name Pf ADH, the original nucleotide sequence is shown in SEQ ID NO.2;
[0053] Alternatively, the alcohol dehydrogenase mutant has the amino acid sequence shown in SEQ ID NO.3;
[0054] The halohydrin dehalogenase is derived from Ilumatobacter coccineus A halohydrin dehalogenase mutant HheG (L103G), wherein the nucleotide sequence of the original halohydrin dehalogenase is shown in SEQ ID NO.6;
[0055] The amino acid sequence of the halohydrin dehalogenase mutant is shown in SEQ ID NO.7, and the nucleotide sequence of the halohydrin dehalogenase mutant is shown in SEQ ID NO.8.
[0056] The encoding gene of the enzyme mutant as described above is shown in SEQ ID NO.4.
[0057] A recombinant plasmid carrying the gene as described above.
[0058] Preferably, the expression vector of the recombinant plasmid is pET28a(+), and the expression host is E.coli BL21(DE3).
[0059] A genetically engineered bacterium expressing the gene as described above.
[0060] The application of the enzyme mutant as described above in the synthesis of chiral S-4-phenyloxazolidinone.
[0061] An alcohol dehydrogenase mutant and a method for cascade catalytic synthesis of chiral S-4-phenyloxazolidinone with a halohydrin dehalogenase, comprising the following steps:
[0062] The alcohol dehydrogenase and halohydrin dehalogenase are present in the form of recombinant cells or crude enzyme solutions for catalysis;
[0063] Wherein, when the alcohol dehydrogenase and halohydrin dehalogenase are present in the form of recombinant cells for catalysis, the amount of alcohol dehydrogenase and halohydrin dehalogenase is 10-100 mg wet cells / ml;
[0064] When the alcohol dehydrogenase and the halohydrin dehalogenase are present in the form of crude enzyme solution for catalysis, the final concentration of the alcohol dehydrogenase and the halohydrin dehalogenase in the reaction system is 10-30 g / L;
[0065] The temperature of the catalytic reaction is 25-35°C, and the time of the catalytic reaction is 2-48 h.
[0066] Preferably, the preparation method of alcohol dehydrogenase and halohydrin dehalogenase in the form of recombinant cells or crude enzyme solution is as follows:
[0067] Expressing alcohol dehydrogenase or halohydrin dehalogenase in a host cell to obtain a recombinant cell; or introducing a nucleic acid molecule capable of expressing alcohol dehydrogenase or halohydrin dehalogenase into the host cell, and inducing expression to obtain a recombinant cell;
[0068] Lysing the recombinant cells to obtain a crude enzyme solution;
[0069] Alternatively, 2-chloroacetophenone is added to the reaction system, and the final concentration of 2-chloroacetophenone in the reaction system is 20-200 mM;
[0070] Alternatively, the catalytic reaction is carried out in a buffer, wherein the buffer is a Tris-HCl buffer with a concentration of 50-100 mM and a pH of 7.0-9.0, and / or a phosphate buffer with a concentration of 50-100 mM and a pH of 6.0-8.0.
[0071] Preferably, the induced expression is to add IPTG to the culture system to a final concentration of 0.1-0.6 mM, and induce the culture at 16-28°C for 10-18 h;
[0072] The nucleic acid molecule capable of expressing alcohol dehydrogenase or halohydrin dehalogenase is introduced into the host cell in the form of a recombinant vector; the recombinant vector is a bacterial plasmid or yeast plasmid carrying a gene encoding the alcohol dehydrogenase or halohydrin dehalogenase;
[0073] The recombinant plasmid specifically replaces the alcohol dehydrogenase or halohydrin dehalogenase coding gene with the restriction site of the pET28a vector. Nde I and Xho I after the small fragment obtained recombinant plasmid.
[0074] The host cell is a prokaryotic cell or a eukaryotic cell; the prokaryotic cell is a bacterium, and the eukaryotic cell is a yeast cell;
[0075] Alternatively, in the alcohol dehydrogenase catalyzed reaction, the coenzyme is specifically reduced coenzyme I, namely NADH or reduced coenzyme II, namely NADPH;
[0076] Wherein, the final concentration of NADH in the reaction system is 50-200 mM;
[0077] The reaction concentration of NaOCN in the reaction system is 1.0-1.5 times the substrate concentration.
[0078] Preferably, the bacteria may be Escherichia coli, preferably E.coli BL21(DE3).
[0079] Specifically, the relevant preparation and detection are as follows:
[0080] Preparation of alcohol dehydrogenase coupled with halohydrin dehalogenase in the present invention S The reaction diagram of -4-phenyloxazolidinone is as follows:
[0081]
[0082] Example 1 Preparation of engineered bacteria producing halohydrin dehalogenase and alcohol dehydrogenase
[0083] The original alcohol dehydrogenase and halohydrin dehalogenase coding genes were codon-optimized and synthesized using Escherichia coli as the host, and the Nde I and Xho I restriction sites, the new enzyme gene was synthesized by Suzhou Hongxun Biotechnology Co., Ltd. The synthesized gene was connected to an expression vector to construct. The expression vector is a conventional vector in the art. The vector of the present invention is specifically pET28a. The recombinant plasmid was transformed into E.coli BL21(DE3) recipient bacteria were plated on LB agar plates containing kanamycin (mass concentration of 50 mg / L) and cultured at 37 °C for 12 h to allow single colonies to grow on the plates. Single colonies were randomly picked and cloned, then inoculated into LB liquid culture medium for 12 h and plasmids were extracted for sequencing. Genetically engineered bacteria were screened out based on the sequencing results and were represented as positive clones. E. coli .
[0084] The coding genes of alcohol dehydrogenase and halohydrin dehalogenase are subjected to site-directed mutagenesis using a site-directed mutagenesis kit to obtain mutants of halohydrin dehalogenase and alcohol dehydrogenase, and then the corresponding genetic engineering strains expressing the halohydrin dehalogenase and alcohol dehydrogenase mutants are obtained according to the above steps.
[0085] Example 2 Expression of alcohol dehydrogenase and halohydrin dehalogenase engineered bacteria
[0086] The recombinant halohydrin dehalogenase engineered bacteria were cultured at 37 °C and 200 r / min for 10 h. The Escherichia coli carrying the recombinant expression plasmid was added to 50 mL LB liquid medium at a 1% inoculum, and kanamycin was added at a final concentration of 50 mg / L. The culture was continued at 37 °C and 200 r / min until the OD 600The value was 0.6-0.8, and IPTG inducer was added to make the final concentration 0.15 mM to induce protein expression. The induction culture was carried out at 28 °C and 200 r / min for about 10 h, and 5000× g The cells were collected by centrifugation for 5 min, resuspended in phosphate buffer (200 mM) at pH 8.0, and disrupted by ultrasonication.
[0087] Example 3 Coupling of wild-type alcohol dehydrogenase, wild-type halohydrin dehalogenase, alcohol dehydrogenase mutant and halohydrin dehalogenase mutant to catalyze the synthesis of 50 mM 2-chloroacetophenone ( S Comparison of )-4-phenyloxazolidinone
[0088] 0.25 g of the wet cells of the wild-type alcohol dehydrogenase and wild-type halohydrin dehalogenase obtained in Example 2, or the wet cells of the alcohol dehydrogenase mutant and the halohydrin dehalogenase mutant (two combinations) were weighed and suspended in 10 mL of a Tris-SO4 buffer system (pH 7.5, 100 mM) containing 60 mM NaOCN and NADH, and 2-chloroacetophenone was added at a final concentration of 50 mM. The mixture was reacted in a constant temperature water bath at 30 °C. After reacting for 3 hours, 900 uL of ethyl acetate was added to the sample, and the mixture was shaken for 20 minutes and centrifuged at 13000 × g for 1 minute. 500 uL of ethyl acetate was taken out, air-dried overnight, and then re-dissolved in 1 ml of a mixed reagent (n-hexane: isopropanol = 1:1, volume ratio), filtered with a 0.22 μm organic membrane, and analyzed.
[0089] The sample analysis conditions are as follows:
[0090] Agilent-1220 system was used, chromatographic column type: Chiralcel OD-H column (Daicel Co., Japan; 4.6×250 mm, 5 μm); chromatographic conditions: column temperature 30 ℃; mobile phase: n-hexane:isopropanol = 80:20 (v / v); flow rate: 1.0 mL / min; UV wavelength was 210 nm; product peak times (min) were: 27.3 and 40.5 respectively.
[0091] Results: The wild-type alcohol dehydrogenase coupled with the wild-type halohydrin dehalogenase, or the alcohol dehydrogenase mutant coupled with the mutant halohydrin dehalogenase mutant, could catalyze the production of 2-chloroacetophenone ( S )-4-phenyloxazolidinone. However, the product yield obtained by the combination of wild-type alcohol dehydrogenase and wild-type halohydrin dehalogenase was only 75%, and the product ( S )-4-phenyloxazolidinone ee>99, but the product contains a small amount of ( S)-5-aryl oxazolidinone (the ratio of the two is 94:6). After the alcohol dehydrogenase mutant and the halohydrin dehalogenase mutant were combined to catalyze the reaction, the yield of the product reached 96.5%, and the product ( S )-4-phenyloxazolidinone ee>99, and the product contains almost no ( S )-5-aryl oxazolidinone impurity.
[0092] Example 3 Coupling of wild-type alcohol dehydrogenase, wild-type halohydrin dehalogenase, alcohol dehydrogenase mutant and halohydrin dehalogenase mutant to catalyze the synthesis of 100 mM 2-chloroacetophenone ( S Comparison of )-4-phenyloxazolidinone
[0093] 0.25 g of the wet cells of the wild-type alcohol dehydrogenase and wild-type halohydrin dehalogenase obtained in Example 2, or the wet cells of the alcohol dehydrogenase mutant and the halohydrin dehalogenase mutant (two combinations) were weighed and suspended in 10 mL of a Tris-SO4 buffer system (pH 7.5, 100 mM) containing 120 mM NaOCN and NADH, and 2-chloroacetophenone was added at a final concentration of 100 mM. The mixture was reacted in a constant temperature water bath at 30 °C. After reacting for 3 hours, 900 uL of ethyl acetate was added to the sample, and the mixture was shaken for 20 minutes and centrifuged at 13000 × g for 1 minute. 500 uL of ethyl acetate was taken out, air-dried overnight, and then re-dissolved in 1 ml of a mixed reagent (n-hexane: isopropanol = 1:1, volume ratio), filtered with a 0.22 μm organic membrane, and analyzed.
[0094] The sample analysis conditions are as follows:
[0095] Agilent-1220 system was used, column type: Chiralcel OD-H column (Daicel Co., Japan; 4.6×250 mm, 5 μm); chromatographic conditions: column temperature 30 °C; mobile phase: n-hexane: isopropanol = 80:20 (v / v); flow rate: 1.0 mL / min; UV wavelength was 210 nm; ( S The elution times (min) of (S)-4-phenyloxazolidinone and (S)-5-aryloxazolidinone were 27.3 and 38.44, respectively.
[0096] Results: The wild-type alcohol dehydrogenase coupled with the wild-type halohydrin dehalogenase, or the alcohol dehydrogenase mutant coupled with the halohydrin dehalogenase mutant, could catalyze the production of 2-chloroacetophenone ( S )-4-phenyloxazolidinone and (S)-5-aryloxazolidinone. However, the product yield obtained by the combination of wild-type alcohol dehydrogenase and wild-type halohydrin dehalogenase was only 63.5%, and the product ( S )-4-phenyloxazolidinone ee>99, but the product contains a small amount of (S )-5-aryl oxazolidinone (the ratio of the two is 93:7) ( Figure 1 As shown). After the alcohol dehydrogenase mutant and the halohydrin dehalogenase mutant were combined to catalyze the reaction, the yield of the product reached 93.5%, and the product ( S )-4-phenyloxazolidinone ee>99, and the product contains almost no ( S )-5-aryl oxazolidinone impurity ( Figure 2 as shown).
[0097] Example 4 Synthesis of 200 mM 2-chloroacetophenone by coupling catalysis of wild-type alcohol dehydrogenase and halohydrin dehalogenase, mutant alcohol dehydrogenase and halohydrin dehalogenase ( S Comparison of )-4-phenyloxazolidinone
[0098] 0.4 g of the wet cells of the wild-type alcohol dehydrogenase and halohydrin dehalogenase obtained in Example 2, or the wet cells of the mutant alcohol dehydrogenase and halohydrin dehalogenase (two combinations) were weighed and suspended in 10 mL of a Tris-SO4 buffer system (pH 7.5, 100 mM) containing 250 mM NaOCN and NADH, and 2-chloroacetophenone was added at a final concentration of 200 mM. The mixture was reacted in a constant temperature water bath at 30 °C. After reacting for 3 hours, 900 uL of ethyl acetate was added to the sample, and the mixture was shaken for 20 minutes and centrifuged at 13000 × g for 1 minute. 500 uL of ethyl acetate was taken out, air-dried overnight, and then re-dissolved in 1 ml of a mixed reagent (n-hexane: isopropanol = 1:1, volume ratio), filtered with a 0.22 μm organic membrane, and analyzed.
[0099] The sample analysis conditions are as follows:
[0100] Agilent-1220 system was used, chromatographic column type: Chiralcel OD-H column (Daicel Co., Japan; 4.6×250 mm, 5 μm); chromatographic conditions: column temperature 30 ℃; mobile phase: n-hexane:isopropanol = 80:20 (v / v); flow rate: 1.0 mL / min; UV wavelength was 210 nm; product peak times (min) were: 27.3 and 38.44 respectively.
[0101] Results: The wild-type alcohol dehydrogenase coupled with the wild-type halohydrin dehalogenase, or the alcohol dehydrogenase mutant coupled with the halohydrin dehalogenase mutant, could catalyze the production of 2-chloroacetophenone ( S )-4-phenyloxazolidinone. However, the product yield obtained by the combination of wild-type alcohol dehydrogenase and wild-type halohydrin dehalogenase was only 61.2%, and the product ( S )-4-phenyloxazolidinone ee>99, but the product contains a small amount of ( S)-5-aryl oxazolidinone (the ratio of the two is 93:7). After the alcohol dehydrogenase mutant and the halohydrin dehalogenase mutant were combined to catalyze the reaction, the yield of the product reached 91.0%, and the product ( S )-4-phenyloxazolidinone ee>99, and the product contains almost no ( S )-5-aryl oxazolidinone impurity.
[0102] The sequences used in the present invention are as follows:
[0103] SEQ ID NO.1 Original alcohol dehydrogenase amino acid sequence
[0104] MKRVNAFNDLKRIGDDKVTAIGMGTWGIGGRETPDYSRDKESIEAIRYGLELGMNLIDTAEFYGAGHAEEIVGEAIKEFEREDIFIVSKVWPTHFGYEEAKKAARASAKRLGTYIDLYLLHWPVDDFKKIEETLHALED LVDEGVIRYIGVSNFNLELLQRSQEVMRKYEIVANQVKYSVKDRWPETTGLLDYMKREGIALMAYTPLEKGTLARNECLAKIGEKYGKTAAQVALNYLIWEENVVAIPKASNKEHLKENFGAMGWRLSEEDREMARRCV
[0105] SEQ ID NO.2 Original alcohol dehydrogenase nucleotide sequence
[0106] ATGAAAAGGGTAAATGCTTTTAACGATCTAAAGCGTATTGGTGATGACAAGGTTACCGCGATCGGCATGGGCACTTGGGGTATTGGCGGTCGTGAGACTCCGGATTACTCTCGTGATAAAGAGAGCATTGAAGCGATCCGTTACGGCCTGGAGTTAGGTATGAACCTGATTGACACCGCTGAGTTCTATGGCGCTGGTCACGCGGAAGAGATTGTGGGTGAAGCGATCAAAGAGTTTGAACGTGAAGACATCTTCATCGTAAGCAAAGTGTGGCCAACGCATTTTGGTTATGAAGAGGCGAAGAAGGCGGCTCGTGCAAGCGCAAAGCGCCTGGGCACCTATATTGACCTGTATCTGTTACATTGGCCGGTCGATGATTTTAAAAAGATTGAAGAGACCTTGCACGCATTGGAGGACCTGGTGGACGAAGGCGTCATCCGCTACATCGGCGTTAGCAACTTCAATCTGGAACTCTTGCAAAGATCGCAAGAAGTTATGCGTAAATACGAGATCGTGGCGAACCAGGTTAAATACTCCGTGAAAGATCGTTGGCCGGAAACCACCGGTCTGCTGGATTACATGAAACGCGAGGGTATTGCACTGATGGCGTATACCCCGCTGGAGAAGGGTACGTTGGCCCGTAATGAATGCCTGGCGAAGATCGGTGAGAAGTACGGCAAAACCGCTGCGCAGGTCGCCCTGAATTATCTTATCTGGGAAGAGAACGTGGTTGCCATCCCGAAAGCCTCCAACAAGGAGCACCTGAAAGAAAACTTCGGCGCTATGGGTTGGCGTCTGAGCGAAGAGGACCGCGAAATGGCGCGCCGCTGTGTT
[0107] SEQ ID NO.3 Mutated Alcohol Dehydrogenase Amino Acid Sequence
[0108] 1MKRVNAFNDLKRIGDDKVTAIGMGTWGIGGRETPDYSRDKESIEAIRYGLELGMNLIDTA
[0109] 61EEYGAGHAEEIVGEAIKEFEREDIFIVSKVTPTHFGYEEAKKAARASAKRLGTYIDLYLL
[0110] 121HWPVDDFKKIEETLHALEDLVDEGVIRYIGVSNFNLELLQRSQEVMRKYEIVANQVKYSV
[0111] 181KDRWPETTGLLDYMKREGIALMAYTPLERGTLARNECLAKIGEKYGKTAAQVALNYLIWE
[0112] 241ENVVAIPKSSNKEHLKENFGAMGWRLSEEDREMARRCV
[0113] SEQ ID NO.4 Mutated Alcohol Dehydrogenase Nucleotide Sequence
[0114] 1ATGAAAAGGGTAAATGCTTTTAACGATCTAAAGCGTATTGGTGATGACAAGGTTACCGCG
[0115] 61ATCGGCATGGGCACTTGGGGTATTGGCGGTCGTGAGACTCCGGATTACTCTCGTGATAAA
[0116] 121GAGAGCATTGAAGCGATCCGTTACGGCCTGGAGTTAGGTATGAACCTGATTGACACCGCT
[0117] 181GAGGAATATGGCGCTGGTCACGCGGAAGAGATTGTGGGTGAAGCGATCAAAGAGTTTGAA
[0118] 241CGTGAAGACATCTTCATCGTAAGCAAAGTGACTCCAACGCATTTTGGTTATGAAGAGGCG
[0119] 301AAGAAGGCGGCTCGTGCAAGCGCAAAGCGCCTGGGCACCTATATTGACCTGTATCTGTTA
[0120] 361CATTGGCCGGTCGATGATTTTAAAAAGATTGAAGAGACCTTGCACGCATTGGAGGACCTG
[0121] 421GTGGACGAAGGCGTCATCCGCTACATCGGCGTTAGCAACTTCAATCTGGAACTCTTGCAA
[0122] 481AGATCGCAAGAAGTTATGCGTAAATACGAGATCGTGGCGAACCAGGTTAAATACTCCGTG
[0123] 541AAAGATCGTTGGCCGGAAACCACCGGTCTGCTGGATTACATGAAACGCGAGGGTATTGCA
[0124] 601CTGATGGCGTATACCCCGCTGGAGAAGGGTACGTTGGCCCGTAATGAATGCCTGGCGAAG
[0125] 661ATCGGTGAGAAGTACGGCAAAACCGCTGCGCAGGTCGCCCTGAATTATCTTATCTGGGAA
[0126] 721GAGAACGTGGTTGCCATCCCGAAAAGTTCCAACAAGGAGCACCTGAAAGAAAACTTCGGC
[0127] 781GCTATGGGTTGGCGTCTGAGCGAAGAGGACCGCGAAATGGCGCGCCGCTGTGTT
[0128] SEQ ID NO.5 Amino acid sequence of the original halohydrin dehalogenase
[0129] MSNAENRPVALITMATGYVGPALARTMADRGFDLVLHGTAGDGTMVGVEESFDSQIADLAKRGADVLTISDVDLTTRTGNQSMIERVLERFGRLDSACLVTGLIVTGKFLDMTDDQWAKVKATNLDMVFHGLQAVLPPMVAAGAGQCVVFTSATGGRPDPMVSIYGGTRAGANGIVRAVGLEHARHGVQVNAIGTNYMDFPGFLKASRADGDPERRAMIEAQVPLRRLGTMDELSSVTAGLLDGSNRFQTGQFFDFSGGWGA
[0130] SEQ ID NO.6 Nucleotide sequence of the original halohydrin dehalogenase
[0131] ATGTCAAATGCAGAAAACAGGCCCGTAGCTCTGATTACGATGGCGACCGGCTACGTGGGTCCGGCACTGGCGCGCACCATGGCTGATCGCGGTTTCGACTTGGTGTTACACGGCACCGCTGGCGATGGGACCATGGTCGGGGTGGAAGAAAGCTTTGACAGCCAGATTGCGGATCTGGCGAAACGCGGCGCCGACGTATTGACCATCAGCGACGTTGATCTGACAACCAGAACTGGTAACCAATCCATGATCGAGCGTGTTCTGGAGCGTTTTGGTCGTCTGGACTCTGCATGTCTGGTGACGGGCTTGATCGTGACCGGTAAGTTCCTCGACATGACCGATGATCAGTGGGCTAAGGTGAAAGCGACCAATCTGGATATGGTGTTCCACGGTCTGCAGGCTGTTCTGCCGCCAATGGTTGCGGCGGGCGCGGGTCAATGCGTTGTGTTTACCAGCGCGACGGGCGGCCGTCCGGACCCGATGGTTTCGATCTATGGTGGCACTCGTGCAGGTGCCAATGGTATTGTTCGCGCAGTCGGCCTTGAGCATGCGCGTCATGGCGTACAGGTCAACGCAATTGGCACGAACTACATGGATTTCCCGGGTTTTCTGAAAGCGTCCCGGGCGGACGGTGACCCGGAGCGTCGTGCCATGATCGAAGCACAAGTTCCGCTGCGCCGTCTGGGTACCATGGATGAATTGTCCTCTGTTACCGCCGGTTTGTTGGACGGTAGCAACCGTTTCCAGACCGGCCAATTCTTCGACTTTAGCGGTGGCTGGGGTGCGTAA
[0132] SEQ ID NO.7 Mutated halohydrin dehalogenase amino acid sequence
[0133] 1MSNAENRPVALITMATGYVGPALARTMADRGFDLVLHGTAGDGTMVGVEESFDSQIADLA
[0134] 61KRGADVLTISDVDLTTRTGNQSMIERVLERFGRLDSACLVTGGIVTGKFLDMTDDQWAKV
[0135] 121KATNLDMVFHGLQAVLPPMVAAGAGQCVVFTSATGGRPDPMVSIYGGTRAGANGIVRAVG
[0136] 181LEHARHGVQVNAIGTNYMDFPGFLKASRADGDPERRAMIEAQVPLRRLGTMDELSSVTAG
[0137] 241LLDGSNRFQTGQFFDFSGGWGA
[0138] SEQ ID NO.8 Mutated Haloalkane Dehalogenase Nucleotide Sequence
[0139] 1ATGTCAAATGCAGAAAACAGGCCCGTAGCTCTGATTACGATGGCGACCGGCTACGTGGGT
[0140] 61CCGGCACTGGCGCGCACCATGGCTGATCGCGGTTTCGACTTGGTGTTACACGGCACCGCT
[0141] 121GGCGATGGGACCATGGTCGGGGTGGAAGAAAGCTTTGACAGCCAGATTGCGGATCTGGCG
[0142] 181AAACGCGGCGCCGACGTATTGACCATCAGCGACGTTGATCTGACAACCAGAACTGGTAAC
[0143] 241CAATCCATGATCGAGCGTGTTCTGGAGCGTTTTGGTCGTCTGGACTCTGCATGTCTGGTG
[0144] 301ACGGGCGGAATCGTGACCGGTAAGTTCCTCGACATGACCGATGATCAGTGGGCTAAGGTG
[0145] 361AAAGCGACCAATCTGGATATGGTGTTCCACGGTCTGCAGGCTGTTCTGCCGCCAATGGTT
[0146] 421GCGGCGGCGCGGGTCAATGCGTTGTGTTTACCAGCGCGACGGGCGGCCGTCCGGACCCG
[0147] 481ATGGTTTCGATCTATGGTGGCACTCGTGCAGGTGCCAATGGTATTGTTCGCGCAGTCGGC
[0148] 541CTTGAGCATGCGCGTCATGGCGTACAGGTCAACGCAATTGGCACGAACTACATGGATTTC
[0149] 601CCGGGTTTTCTGAAAGCGTCCCGGGCGGACGGTGACCCGGAGCGTCGTGCCATGATCGAA
[0150] 661GCACAAGTTCCGCTGCGCCGTCTGGGTACCATGGATGAATTGTCCTCTGTTACCGCCGGT
[0151] 721TTGTTGGACGGTAGCAACCGTTTCCAGACCGGCCAATTCTTCGACTTTAGCGGTGGCTGG
[0152] 781GGTGCGTAA
[0153] Although the embodiments of the present invention are disclosed for illustrative purposes, those skilled in the art will appreciate that various substitutions, changes and modifications are possible without departing from the spirit and scope of the present invention and the appended claims. Therefore, the scope of the present invention is not limited to the contents disclosed in the embodiments.
Claims
1. An enzyme mutant with improved enzyme activity, characterized in that: The enzyme mutant is an alcohol dehydrogenase mutant or a halohydrin dehalogenase mutant. The amino acid sequence of the alcohol dehydrogenase mutant is shown in SEQ ID NO.3, and the amino acid sequence of the halohydrin dehalogenase mutant is shown in SEQ ID NO.
7.
2. The encoding gene of the enzyme mutant according to claim 1, wherein the encoding gene of the alcohol dehydrogenase mutant is shown in SEQ ID NO.4, and the encoding gene of the halohydrin dehalogenase mutant is shown in SEQ ID NO.
8.
3. A recombinant plasmid carrying the coding gene as claimed in claim 2.
4. A genetically engineered bacterium containing the coding gene according to claim 2.
5. Use of the alcohol dehydrogenase mutant or halohydrin dehalogenase mutant according to claim 1 in the synthesis of chiral S-4-phenyloxazolidinone, characterized in that: Alcohol dehydrogenase mutants and halohydrin dehalogenase mutants catalyze 2-chloroacetophenone to produce chiral S-4-phenyloxazolidinone in the same reaction system.
6. A method for synthesizing chiral S-4-phenyloxazolidinone by cascade catalysis of an alcohol dehydrogenase mutant and a halohydrin dehalogenase mutant, characterized in that: The steps include: The alcohol dehydrogenase mutant and the halohydrin dehalogenase mutant catalyze 2-chloroacetophenone in the form of recombinant cells or crude enzyme solutions; Wherein, when the alcohol dehydrogenase mutant and the halohydrin dehalogenase mutant are catalyzed in the form of recombinant cells, the amount of the alcohol dehydrogenase mutant and the halohydrin dehalogenase mutant is 10-100 mg wet cells / ml; When the alcohol dehydrogenase mutant and the halohydrin dehalogenase mutant are present in the form of crude enzyme solution for catalysis, the final concentration of the alcohol dehydrogenase mutant and the halohydrin dehalogenase mutant in the reaction system is 10-30 g / L; The temperature of the catalytic reaction is 25-35 °C, and the time of the catalytic reaction is 2-48 h; The amino acid sequence of the alcohol dehydrogenase mutant is shown in SEQ ID NO.3, and the amino acid sequence of the halohydrin dehalogenase mutant is shown in SEQ ID NO.
7.
7. The method according to claim 6, characterized in that: The preparation method of the alcohol dehydrogenase mutant and the halohydrin dehalogenase mutant in the form of recombinant cells or crude enzyme solution is as follows: Expressing an alcohol dehydrogenase mutant or a halohydrin dehalogenase mutant in a host cell to obtain a recombinant cell; or introducing a nucleic acid molecule capable of expressing an alcohol dehydrogenase mutant or a halohydrin dehalogenase mutant into a host cell, and obtaining a recombinant cell after inducing expression; The recombinant cells are lysed to obtain a crude enzyme solution.
8. The method according to claim 7, characterized in that: The induced expression is to add IPTG to the culture system to a final concentration of 0.1-0.6 mM, and induce culture at 16-28° C. for 10-18 h; The nucleic acid molecule capable of expressing the alcohol dehydrogenase mutant or the halohydrin dehalogenase mutant is introduced into the host cell in the form of a recombinant vector; the recombinant vector is a bacterial plasmid or a yeast plasmid carrying a gene encoding the alcohol dehydrogenase mutant or the halohydrin dehalogenase mutant; The host cell is a prokaryotic cell or a eukaryotic cell; the prokaryotic cell is a bacterium, and the eukaryotic cell is a yeast cell.
